Vancomycin Powder for Fractures
(POWDER Trial)
Trial Summary
What is the purpose of this trial?
This is the first prospective controlled study to determine whether the topical application of vancomycin powder reduces infection-related complications when applied to open fracture injuries in the acute emergency department setting.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are using a high-potency antibiotic powder or solution on your wound, you may not be eligible to participate.
What data supports the effectiveness of the drug Vancomycin Powder for treating fractures?
Is vancomycin powder safe for use in humans?
How is the drug Vancomycin Powder unique for treating fractures?
Vancomycin Powder is unique because it is applied directly to the surgical site during fracture surgery, which helps reduce the risk of infection, particularly from Staphylococcus aureus, without causing significant side effects like nephrotoxicity (kidney damage). This local application is different from traditional systemic antibiotic treatments that are taken orally or injected.210111213
Research Team
Robert A De Lorenzo, MD
Principal Investigator
University of Texas
Eligibility Criteria
Adults over 18 with open fractures of certain bones who can consent to the study within 24 hours of injury. Excluded are those treated with high-potency antibiotics, allergic to vancomycin, pregnant women, prisoners, and subjects already operated on for the fracture elsewhere.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive usual care plus topical application of 2 grams of vancomycin powder to open fracture wounds in the emergency room
Follow-up
Participants are monitored for infection-related complications and other outcomes
Treatment Details
Interventions
- Vancomycin
Vancomycin is already approved in United States, European Union, Canada, Japan for the following indications:
- Severe infections caused by susceptible strains of methicillin-resistant staphylococci
- Enterocolitis caused by Staphylococcus aureus
- Staphylococcal endocarditis
- Severe infections caused by Gram-positive bacteria
- Endocarditis
- Peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD)
- Severe infections caused by susceptible strains of methicillin-resistant staphylococci
- Enterocolitis caused by Staphylococcus aureus
- Severe infections caused by Gram-positive bacteria
- Endocarditis
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center at San Antonio
Lead Sponsor
United States Army Institute of Surgical Research
Collaborator
San Antonio Military Medical Center
Collaborator